Abstract
The SARS-CoV-2 pandemic that causes COVID-19 respiratory syndrome has caused global public health and economic crises, necessitating rapid development of vaccines and therapeutic countermeasures. The world-wide response to the COVID-19 pandemic has been unprecedented with government, academic, and private partnerships working together to rapidly develop vaccine and antibody countermeasures. Many of the technologies being used are derived from prior government-academic partnerships for response to other emerging infections.
Keywords:
▪▪▪.
Copyright © 2020 Elsevier Inc. All rights reserved.
MeSH terms
-
AIDS Vaccines / immunology
-
Animals
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / immunology
-
Antibodies, Neutralizing / chemistry
-
Antibodies, Neutralizing / immunology
-
Antibodies, Viral / chemistry
-
Antibodies, Viral / immunology
-
Betacoronavirus / physiology
-
COVID-19
-
COVID-19 Drug Treatment
-
COVID-19 Vaccines
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / immunology
-
Coronavirus Infections / prevention & control*
-
Humans
-
Intersectoral Collaboration
-
Pandemics / prevention & control*
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / prevention & control*
-
SARS-CoV-2
-
Viral Vaccines / chemistry
-
Viral Vaccines / immunology*
Substances
-
AIDS Vaccines
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
COVID-19 Vaccines
-
Viral Vaccines